Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease.

ABSTRACT:

Background

The clinical course of COVID-19 patients ranges from asymptomatic infection, via mild and moderate illness, to severe disease and even fatal outcome. Biomarkers which enable an early prediction of the severity of COVID-19 progression, would be enormously beneficial to guide patient care and early intervention prior to hospitalization.

Methods

Here we describe the identification of plasma protein biomarkers using an antibody microarray-based approach in order to predict a severe cause of a COVID-19 disease already in an early phase of SARS-CoV-2 infection. To this end, plasma samples from two independent cohorts were analyzed by antibody microarrays targeting up to 998 different proteins.

Results

In total, we identified 11 promising protein biomarker candida

SUBMITTER: Hufnagel K 

PROVIDER: S-EPMC10089829 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature